Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients – a safe but futile intervention. A comparative cohort study

References

• Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 test sensitivity – a strategy for containment. N Engl J Med. 2020;383:e120.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–1423.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for disease control and prevention. JAMA. 2020;323(13):1239–1242.
   PubMed Web of Science ®Google Scholar
• Hou W, Zhang W, Jin R, et al. Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study. Infectious Diseases. 2020;52(7):498–505.
   PubMed Web of Science ®Google Scholar
• Bentivegna E, Sentimentale A, Luciani M, et al. New IgM seroconversion and positive RT‐PCR test after exposure to the virus in recovered COVID‐19 patient. J Med Virol. 2021;93(1):97–98.
   PubMed Web of Science ®Google Scholar
• Brown JF, Dye JM, Tozay S, et al. Anti-Ebola virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with ebola virus disease. J Infect Dis. 2018;218(4):555–562.
   PubMed Web of Science ®Google Scholar
• Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis. 1999;179(s1):S18–S23.
   PubMedGoogle Scholar
• Takada A, Feldmann H, Ksiazek TG, et al. Antibody-dependent enhancement of Ebola virus infection. J Virol. 2003;77(13):7539–7544.
   PubMed Web of Science ®Google Scholar
• Xu D, Zhou F, Sun W, et al. Relationship between serum severe acute respiratory syndrome Coronavirus 2 Nucleic acid and organ damage in Coronavirus 2019 patients: a cohort study. Clin Infect Dis. 2020;2020:ciaa1085.
   Google Scholar
• Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90.
   PubMed Web of Science ®Google Scholar
• Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447–456.
   PubMed Web of Science ®Google Scholar
• Soo YOY, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10(7):676–678.
   PubMed Web of Science ®Google Scholar
• Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama. 2020;323(16):1582.
   PubMed Web of Science ®Google Scholar
• Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490–9496.
   PubMed Web of Science ®Google Scholar
• Zeng Q-L, Yu Z-J, Gou J-J, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with Coronavirus Disease 2019. J Infect Dis. 2020;222(1):38–43.
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. Cold Spring Harbor Laboratory. 2020.
   PubMedGoogle Scholar
• Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. Jama. 2020;324(5):460.
   PubMed Web of Science ®Google Scholar
• Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610–618.
   PubMed Web of Science ®Google Scholar
• Rogers R, Shehadeh F, Mylona EK, et al. Convalescent plasma for patients with severe COVID-19: a matched cohort study. Clin Infect Dis. 2020;2020:ciaa1548.
   Google Scholar
• Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384(7):619–629.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). Bmj. 2020;:m3939.
   PubMedGoogle Scholar
• Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. Jama. 2020;323(16):1561–1562.
   PubMed Web of Science ®Google Scholar
• Traugott M, Aberle SW, Aberle JH, et al. Performance of severe acute respiratory syndrome Coronavirus 2 antibody assays in different stages of infection: comparison of commercial enzyme-linked immunosorbent assays and rapid tests. J Infect Dis. 2020;222(3):362–366.
   PubMed Web of Science ®Google Scholar
• Weidner L, Gänsdorfer S, Unterweger S, et al. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays. J Clin Virol. 2020;129:104540.
   PubMed Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–2668.
   PubMed Web of Science ®Google Scholar
• Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576–588.
   PubMedGoogle Scholar
• Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:633–659.
   PubMed Web of Science ®Google Scholar
• Seitz T, Hoepler W, Weseslindtner L, et al. Successful management of the first reported case in Austria of COVID-19 with ARDS. Infection. 2020;48(4):647–651.
   PubMed Web of Science ®Google Scholar
• Bentivegna E, Luciani M, Spuntarelli V, et al. Extremely severe case of COVID-19 pneumonia recovered despite bad prognostic indicators: a didactic report. SN Compr Clin Med. 2020;2(8):1204–1207.
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 – final report. N Engl J Med. 2020;383(19):1813–1826.
   PubMed Web of Science ®Google Scholar
• WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 – interim WHO solidarity trial results. New Eng J Med. 2020;384(6):497–511.
   PubMed Web of Science ®Google Scholar
• Pennica A, Conforti G, Falangone F, et al. Clinical management of adult Coronavirus Infection Disease 2019 (COVID-19) positive in the setting of low and medium intensity of care: a short practical review. SN Compr Clin Med. 2020;2(6):694–699.
   PubMedGoogle Scholar
• RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 – preliminary report. New Eng J Med. 2020;384(8):693–704.
   PubMed Web of Science ®Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19). JAMA. 2020;323(18):1824–1836.
   PubMed Web of Science ®Google Scholar
• Lane HC, Fauci AS. Research in the context of a pandemic. New Eng J Med. 2020;384:755–757.
   PubMed Web of Science ®Google Scholar
• ACTIV-3/TICO LY-CoV555 Study Group. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. New Eng J Med. 2020;384:905–914.
   PubMed Web of Science ®Google Scholar
• Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384(3):229–237.
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238–251.
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;384(11):1015–1027.
   PubMed Web of Science ®Google Scholar
• Koblischke M, Traugott MT, Medits I, et al. Dynamics of CD4 T cell and antibody responses in COVID-19 patients with different disease severity. Front Med. 2020;7:592629.
   Web of Science ®Google Scholar
• Jenkins MM, McCaw TR, Goepfert PA. Mechanistic inferences from clinical reports of SARS-CoV-2. Infect Dis. 2020;52(8):527–537.
   PubMed Web of Science ®Google Scholar